# Biodesix Inc. (BDSX)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $113M  
**Price:** $15.01 (-2.28%)

> Biodesix Inc. is a leading diagnostic solutions company specializing in blood-based molecular diagnostics for lung disease and oncology. It provides advanced diagnostic testing services, including the Nodify Lung suite such as Nodify CDT® and Nodify XL2® for lung nodule risk assessment, and IQLung for cancer treatment guidance. Additional tests encompass VeriStrat® for proteomic stratification in non-small cell lung cancer, GeneStrat® for genomic mutation detection via next-generation sequencing, and other offerings supporting precision oncology. Biodesix Inc. operates CLIA-certified, CAP-accredited laboratories employing technologies like proteomics, genomics, droplet digital PCR, and mass spectrometry to enable noninvasive, personalized clinical decisions for pulmonologists and oncologists. Complementing its diagnostics, the company delivers development services to biopharmaceutical and life sciences partners, including diagnostic research, clinical trial testing, companion diagnostics development, and commercialization support. These services facilitate innovation in precision medicine across lung cancer, breast cancer, and related areas. Headquartered in Louisville, Colorado, Biodesix Inc. plays a vital role in enhancing patient outcomes through timely, evidence-based diagnostic insights in the healthcare sector.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $88M | — | -$28M | -$35M | — |
| 2024 | $71M | — | -$34M | -$43M | — |
| 2023 | $49M | — | -$41M | -$52M | — |
| 2022 | $38M | — | -$51M | -$65M | — |
| 2021 | $55M | — | -$41M | -$43M | — |
| 2020 | $46M | — | -$23M | -$65M | — |
| 2019 | $25M | — | -$27M | -$31M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $87M | $90M | -$2M | $19M | $50M |
| 2024 | $97M | $76M | $21M | $26M | $40M |
| 2023 | $99M | $95M | $5M | $26M | $40M |
| 2022 | $93M | $72M | $21M | $43M | $30M |
| 2021 | $76M | $56M | $20M | $33M | $10M |
| 2020 | $121M | $80M | $41M | $62M | $28M |
| 2019 | $45M | $76M | -$225M | $5M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$23M | $259,000 | -$24M |
| 2024 | -$49M | $3M | -$52M |
| 2023 | -$23M | $23M | -$46M |
| 2022 | -$45M | $3M | -$48M |
| 2021 | -$28M | $2M | -$30M |
| 2020 | -$21M | $2M | -$23M |
| 2019 | -$22M | $1M | -$23M |

Source: [CompaniesByCap](https://companiesbycap.com/company/BDSX)